NCT02650817

Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer

A Phase IB Study to Evaluate the Effect of RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer Lesions Using 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography Imaging

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Stemline Therapeutics, Inc. · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to visualize and quantify ER-binding sites during treatment with Elacestrant (RAD1901)

Detailed description

The purpose of this study is to visualize and quantify ER-binding sites during treatment with Elacestrant (RAD1901) using 16α-18F-Fluoro-17β-estradiol (FES) positron emission tomography (PET) imaging

Conditions

• Metastatic Breast Cancer

Interventions

Type	Name	Description
DRUG	RAD1901	RAD1901, a novel selective ER degrader (SERD)

Timeline

• Start date: 2016-04-01
• Primary completion: 2018-08-30
• Completion: 2019-10-18
• First posted: 2016-01-08
• Last updated: 2022-08-18

Locations

5 sites across 2 countries: Belgium, Netherlands

Regulatory

• FDA-regulated drug study